The first full year of operations of your Company as a part of the
 Pfizer group, the worlds largest biopharmaceutical company, has been
 replete with milestones in sales, marketing and manufacturing.
 
 This report details the robust sales and growth achieved during the
 year.
 
 Your Company continues to dominate the market in oral contraceptives
 and hormone therapy.
 
 With a view to consolidate our position and grow faster, your Company
 is launching new Branded Value Offerings (BVOs) in Womens Health and
 Anti-Infectives, two areas where your Company has rich experience and
 heritage brands.
 
 Wyeths success in vaccines is well known. I am glad to report that
 sales of Prevenar 13, our new generation pneumococcal conjugate
 vaccine, continue to be buoyant. The vaccine is the largest selling
 toddler vaccine in the country. Your Company received the Award for
 Marketing Excellence instituted by the Organisation of Pharmaceutical
 Producers of India (OPPI) for Prevenar.
 
 Our manufacturing plant in Goa is the proud winner of the India
 Manufacturing Excellence Award (IMEA) for 2010 jointly instituted by
 The Economic Times newspaper and the global consulting firm, Frost &
 Sullivan (F&S) and acknowledges the best facilities in India that have
 achieved and sustained manufacturing excellence.
 
 The Indian health care market is poised to grow on the back of the
 growing economy, rising health awareness and increasing disposable
 income. Wyeth is determined to tap into new opportunities to serve the
 health care needs of the worlds second largest population.
 
 I look forward to your continued support.
 
 
 
 
 Regards
 
 Kewal Hauda
 Managing Director 
 Wyeth Limited